IMR Press / CEOG / Volume 41 / Issue 2 / DOI: 10.12891/ceog17022014

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Case Report
Can laparoscopic removal of Essure device before embryo transfer correct poor reproductive outcome pattern in IVF? A case report
Show Less
1 Pacific Reproductive Center, Irvine, CA (USA)
2 HRC Fertility-Encino, Los Angeles, CA (USA)
3 Division of Applied Biotechnology, School of Life Sciences, University of Westminster, London (United Kingdom)
Clin. Exp. Obstet. Gynecol. 2014, 41(2), 219–222; https://doi.org/10.12891/ceog17022014
Published: 10 April 2014
Abstract

Objective: This report describes a successful surgical approach to multiple in vitro fertilization (IVF) failures in the setting of hydrosalpinges, which had been previously treated with Essure inserts. Materials and Methods: A non-smoking 33-year-old Caucasian G2 P0020 (body mass index: BMI = 22) attended for second opinion. Her history was significant for bilateral hydrosalpinges having been noted on hysterosalpingogram two years earlier. This was managed by hysteroscopic placement of Essure inserts bilaterally. One year later, and now with Essure in situ, the patient completed three IVF cycles elsewhere. Her first and third IVF attempts resulted in biochemical pregnancy, while human chorionic gonadotropin (hCG) was negative after the second cycle. Upon presentation at the authors’ center and before beginning a fourth IVF cycle, further testing and surgical removal of the Essure devices was recommended. Results: Repeat hysteroscopy was unremarkable; laparoscopic bilateral salpingectomy and extirpation of Essure implants was accomplished without difficulty. Following menses, the patient initiated IVF with three embryos transferred. At day 60, a single intrauterine pregnancy was identified with positive cardiac activity (rate >100/min). Her obstetrical course was uneventful; a healthy 4,195 gram male infant was delivered (breech) by Cesarean at 40 weeks’ gestation. Conclusion: Essure inserts comprise inner fibers of polyethylene terephthalate, a stainless steel coil, and a nickeltitanium coil. The product received FDA approval as a contraceptive in 2002 although its use for hydrosalpinx remains off-label. While successful outcomes with IVF following Essure placement have been reported, this is the first description of pregnancy and delivery from IVF after Essure removal. Essure may be considered for sterilization when laparoscopy is contraindicated, but experience with its use specifically for treating hydrosalpinges before IVF is limited. This observed association between prior poor IVF outcomes and Essure with subsequent delivery after surgical Essure removal is the first of its kind to be reported, and warrants further investigation.
Keywords
Essure
Hydrosalpynx
IVF
Recurrent miscarriage
Laparoscopy
Share
Back to top